LEVAQUIN 500MG DIN 02236842
Health Canada record
| Active ingredient(s) | LEVOFLOXACIN 500 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | J01MA12 LEVOFLOXACIN |
| Original market date | 28-Nov-1997 |
| Current status date | 02-Apr-2015 |
| Source | Health Canada DPD |
Establishment licence of the holder
Janssen Inc — licence 100239, currently licensed, last inspection rating C (2026-03-09).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing LEVOFLOXACIN
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02537079 | LEVOFLOXACIN IN 5% DEXTROSE INJECTION | HIKMA CANADA LIMITED | Solution | LEVOFLOXACIN 5 MG | Marketed |
| 02314932 | LEVOFLOXACIN IN 5% DEXTROSE INJECTION | PFIZER CANADA ULC | Solution | LEVOFLOXACIN 5 MG | Marketed |
| 02460122 | LEVOFLOXACIN IN 5% DEXTROSE INJECTION | STERIMAX INC | Solution | LEVOFLOXACIN 5 MG | Approved |
| 02361027 | AVA-LEVOFLOXACIN | AVANSTRA INC | Tablet | LEVOFLOXACIN 250 MG | Cancelled Post Market |
| 02361035 | AVA-LEVOFLOXACIN | AVANSTRA INC | Tablet | LEVOFLOXACIN 500 MG | Cancelled Post Market |
| 02236841 | LEVAQUIN | JANSSEN INC | Tablet | LEVOFLOXACIN 250 MG | Cancelled Post Market |
| 02236840 | LEVAQUIN 25MG/ML | JANSSEN INC | Solution | LEVOFLOXACIN 25 MG | Cancelled Post Market |
| 02236839 | LEVAQUIN 5MG/ML | JANSSEN INC | Solution | LEVOFLOXACIN 5 MG | Cancelled Post Market |
| 02246804 | LEVAQUIN 750MG | JANSSEN INC | Tablet | LEVOFLOXACIN 750 MG | Cancelled Post Market |
| 02358670 | NTP-LEVOFLOXACIN | TEVA CANADA LIMITED | Tablet | LEVOFLOXACIN 750 MG | Cancelled Pre Market |
| 02358662 | NTP-LEVOFLOXACIN | TEVA CANADA LIMITED | Tablet | LEVOFLOXACIN 500 MG | Cancelled Pre Market |
| 02358654 | NTP-LEVOFLOXACIN | TEVA CANADA LIMITED | Tablet | LEVOFLOXACIN 250 MG | Cancelled Pre Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 15986 | 2014-08-20 | Supplement to a New Drug Submission (SNDS) | REMOVAL OF REFERENCES TO THE DISCONTNIUED IV FORMULATION FROM PM |
| 3909 | 1997-11-14 | New Drug Submission (NDS) |
International API supply for LEVOFLOXACIN
23 active FDA Drug Master Files.
Request a quote for LEVAQUIN 500MG